Susan Jara

Featured in: Favicon

msn.com

rd.com

thehealthy.com Favicon

readersdigest.ca Favicon

besthealthmag.ca Favicon

creakyjoints.org Favicon

selection.ca Favicon

southfloridareporter.com

Articles

Neuroimmune Modulation

Nov 25, 2024 | creakyjoints.org | Susan Jara

At the 2024 American College of Rheumatology (ACR) Convergence, patients, clinicians, and researchers came together to discuss an innovative treatment for rheumatoid arthritis (RA): neuroimmune modulation. This therapy is a first-of-its-kind treatment for people living with moderate-to-severe RA who haven’t found relief from at least one biologic or targeted medication or can’t tolerate them.
GHLF brings Innovative and Patient-Centered Research to ACR

Nov 14, 2024 | ghlf.org | Susan Jara

FOR IMMEDIATE RELEASE MEDIA CONTACTSusan JaraPhone: 201-406-7756Email: Upper Nyack, NY (November, 14, 2024) — The Global Healthy Living Foundation (GHLF) is excited to present innovative and transformative research at the American College of Rheumatology (ACR) Convergence 2024 in Washington DC. This marks GHLF’s ninth consecutive year presenting at ACR, coinciding with the 10th anniversary of PatientSpot, the patient-powered research registry formerly known as ArthritisPower.
6 Myths About Hidradenitis Suppurativa That May Harm Patients

Jun 6, 2024 | ghlf.org | Susan Jara

Pronouncing hidrandenitis suppurativa (hi-dray-deh-NYE-tis sup-yur-AH-tiv-uh, if you’re curious) isn’t the most challenging part of managing this chronic skin condition. HS is tricky to learn about because it’s not exactly a household name — not many people have heard about it, and misconceptions about who gets HS, its symptoms, treatment, and more can harm those who suspect they may have it or who are already living with it.
CGRP-Therapies Endorsed as a First-Line Migraine Treatment

Mar 14, 2024 | ghlf.org | Susan Jara

The American Headache Society (AHS) has released an updated consensus statement that could transform how migraine is treated. The statement, which was published in Headache: The Journal of Head and Face Pain, suggests therapies targeting calcitonin gene-related peptide (CGRP), which include monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) and small-molecule CGRP receptor antagonists (rimegepant and atogepant), as a first-line option for preventing migraine attacks.
Medicaid Flu Vaccination Rates, Pharmacy Reimbursement

Feb 27, 2024 | ghlf.org | Susan Jara

FOR IMMEDIATE RELEASE MEDIA CONTACTSusan JaraPhone: 201-406-7756Email: UPPER NYACK, NY — The Global Healthy Living Foundation (GHLF) co-released a groundbreaking report that found a direct link between pharmacy reimbursement and flu vaccination rates among Medicaid-covered adults.
Unveiling the Impact of COVID-19 Vaccines

Feb 16, 2024 | creakyjoints.org | Susan Jara

As COVID-19 variants continue to pose new challenges, many wonder: Are COVID-19 shots still necessary? A recent groundbreaking paper by the Progressive Policy Institute (PPI) provides crucial insights into this question.
Krys Baxter's Journey

Nov 30, 2023 | ghlf.org | Susan Jara

Krys Baxter’s journey toward their inflammatory bowel disease (IBD) diagnosis hasn’t been easy. They’ve dealt with severe stomach pain since they were five years old, describing it as feeling like “someone was just stabbing me repeatedly in the stomach, and twisting the knife.”This pain stuck with them through childhood and teenage years, leading to many hospital visits and tests. Unfortunately, they often felt like no one was really listening.
FDA Approves Zepbound for Obesity

Nov 10, 2023 | ghlf.org | Susan Jara

The FDA has given the green light to Zepbound, a weekly self-injection designed to help adults with obesity effectively manage their weight. This development brings new hope to those confronting health challenges related to obesity. Zepbound is approved for adults with a body mass index (BMI) of 30 or higher or for individuals with a BMI of 27 who also have a weight-related condition like high blood pressure or heart disease.
IgG4-RD Archives - CreakyJoints

Oct 30, 2023 | creakyjoints.org | Esteban Rivera |Shelley Fritz |Susan Jara

Login to comment on posts, connect with other members, access special offers and view exclusive content. Only fill in if you are not human
FDA Approves Omvoh for Ulcerative Colitis

Oct 27, 2023 | ghlf.org | Susan Jara

Adults living with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease that affects millions of individuals worldwide, now have a new treatment option. On October 26, the U.S. Food and Drug Administration (FDA) approved Omvoh (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL) for the treatment of this condition.